Blocking Nitrosylation: A Breakthrough Strategy for Treating Aggressive NRAS Melanoma
核心洞察
Moffitt Cancer Center researchers discovered that blocking nitrosylation makes aggressive NRAS (搜索)-mutant melanoma (搜索) more responsive to treatment, enhancing both drug efficacy and immune response against the cancer.
NRAS (搜索)-mutant melanoma (搜索), accounting for approximately 25 percent of melanoma cases, has historically had limited treatment options due to its resistance to both immunotherapies and targeted drugs.
The study found that inhibiting nitrosylation significantly increases cancer cells' sensitivity to MEK inhibitors (搜索) and triggers immunogenic cell death, drawing in critical immune cells to fight the tumor.
Researchers at Moffitt Cancer Center have discovered a promising new approach to treating one of the most aggressive forms of melanoma (搜索). By blocking a chemical process called nitrosylation, scientists were able to make NRAS (搜索)-mutant melanoma more responsive to existing treatments while simultaneously boosting the body's immune response against the cancer.
NRAS (搜索)-mutant melanoma (搜索), which accounts for approximately 15-25 percent of all melanoma cases, has historically been difficult to treat, with patients having few effective options. This aggressive cancer typically resists both targeted therapies and immunotherapies.
"NRAS (搜索)-mutant melanoma (搜索) has very few effective treatment options," explained Dr. Sanjay Premi, co-lead author and assistant member in the Tumor Microenvironment and Metastasis Department at Moffitt. "Our research aims to change that."
Understanding Nitrosylation in Cancer
Nitrosylation is a chemical modification caused by nitric oxide that helps cancer cells evade both treatments and the body's immune system. The Moffitt team discovered that NRAS (搜索)-mutant melanomas often have overactive nitric oxide synthases (搜索) (NOS), which are associated with worse patient outcomes.
In their study published in Cancer Research, the researchers demonstrated that blocking nitrosylation significantly weakened the cancer's defenses.
"When we block nitrosylation, we kill the cancer cells and help the immune system attack the tumor," Premi explained.
The team specifically examined how nitrosylation interacts with MEK inhibitors (搜索), drugs that target the MEK-ERK (搜索) signaling pathway—a crucial driver of tumor growth in NRAS (搜索)-mutant melanoma (搜索). Their findings showed that inhibiting nitrosylation made cancer cells significantly more sensitive to these drugs, resulting in slower tumor growth in both laboratory experiments and animal models.
Dual Mechanism of Action
One of the most significant discoveries was that blocking nitrosylation not only made the cancer more vulnerable to drugs but also induced immunogenic cell death—a process that causes tumor cells to emit distress signals that attract CD8-positive T cells and dendritic cells, key components of the immune system's cancer-fighting arsenal.
"This approach not only restricts tumor growth but also enhances the body's own anti-cancer immune response," said Dr. Jyoti Srivastava, co-lead author and senior research scientist at Moffitt. "It could lead to more durable responses for patients who currently have limited options."
Identifying Specific Targets
The researchers have identified specific proteins and sites where nitrosylation modifications occur, opening the door to developing targeted molecules against these particular sites or proteins.
"We have simply started scratching the surface in this field, especially nitrosylation," Premi noted in an interview. "We have identified hundreds of proteins, and we have characterized the function of only two so far."
Future Directions
The Moffitt team is now investigating combination therapies involving nitrosylation inhibitors, not only for melanoma (搜索) but potentially for other cancers as well. They believe this approach could target multiple cancer pathways simultaneously.
"As expected with any cancer where multiple things are going wrong in several different directions, you cannot use simply one drug to cure cancer," Premi explained. "We think, and we hope, that nitrosylation blocking will be a strategy which will target several different pathways simultaneously."
This research represents a significant step forward in addressing the unmet medical need for effective treatments for NRAS (搜索)-mutant melanoma (搜索). By targeting the fundamental mechanisms that help cancer cells survive and evade the immune system, this approach could potentially transform outcomes for patients with this aggressive form of skin cancer.